Find a Trial

Trial Results


17 protocol(s) meet the specified criteria
20170543OPEN TO ACCRUAL
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
BTCRC-LUN17-139OPEN TO ACCRUAL
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1, T4N0-1] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCC-0726OPEN TO ACCRUAL
Significance of STK11/LKB1 or Keap1 mutations in Stage III Non-Small Cell Lung Cancer
CTO-LUN18-335OPEN TO ACCRUAL
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
LUN17-302OPEN TO ACCRUAL
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
LUN17-321OPEN TO ACCRUAL
A Phase II study of Concurrent Chemoradiation plus Durvalumab followed by Surgery followed by Adjuvant Durvalumab in medically operable patients with surgically resectable Stage IIIA (N2) Non-Small Cell Lung Cancer
NRG-LU003OPEN TO ACCRUAL
A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master Protocol